Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.31 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29885718 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTCA12GMNNCA1 | |
| SCHEMBL27526921 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTCA12GMNNCA1 | |
| SCHEMBL29886257 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTCA12GMNNCA1 | |
| SCHEMBL15454179 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTCA12GMNNCA1 | |
| SCHEMBL375061 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTCA12GMNNCA1 | |
| Methane SCHEMBL11881987 | 0.97 | ALDH1A1 (0.41) | ALDH1A1MAPTCA12GMNNCA1 | |
| SCHEMBL30595060 | 0.97 | ALDH1A1 (0.41) | ALDH1A1MAPTCA12GMNNCA1 | |
| Barium SCHEMBL29897735 | 0.97 | ALDH1A1 (0.41) | ALDH1A1MAPTCA12GMNNCA1 | |
| SCHEMBL3003480 | 0.97 | ALDH1A1 (0.38) | ALDH1A1MAPTCA12GMNNCA1 | |
| SCHEMBL12475384 | 0.97 | ALDH1A1 (0.47) | ALDH1A1HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215128-B2 | (Pyridinylmethyl)butanediamine derivatives that chelate copper | COLD SPRING HARBOR LABORATORY (US) | 2025-02-04 | — | — | US | claimed |
| EP-3823977-A1 | (PYRIDINYLMETHYL)BUTANEDIAMINE DERIVATIVES THAT CHELATE COPPER | Cold Spring Harbor Laboratory (US) | 2021-05-26 | — | — | EP | claimed |
| WO-2020018893-A1 | (PYRIDINYLMETHYL)BUTANEDIAMINE DERIVATIVES THAT CHELATE COPPER | COLD SPRING HARBOR LABORATORY (US) | 2020-01-23 | — | — | WO | claimed |
| US-9273342-B2 | Methods and systems for evaluating and predicting the reactivity of monooxygenase enzymes | UNIVERSITY OF ROCHESTER (US) | 2016-03-01 | — | — | US | claimed |
| US-20140038850-A1 | METHODS AND SYSTEMS FOR EVALUATING AND PREDICTING THE REACTIVITY OF MONOOXYGENASE ENZYMES | UNIVERSITY OF ROCHESTER (US) | 2014-02-06 | — | — | US | claimed |
| WO-2012109586-A2 | METHODS AND SYSTEMS FOR EVALUATING AND PREDICTING THE REACTIVITY OF MONOOXYGENASE ENZYMES | UNIVERSITY OF ROCHESTER (US) | 2012-08-16 | — | — | WO | claimed |
| US-20260132258-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, METHOD FOR MANUFACTURING ARTICLE, AND ARTICLE | AGC Inc. (JP) | 2026-05-14 | — | — | US | disclosed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| US-12215128-B2 | (Pyridinylmethyl)butanediamine derivatives that chelate copper | COLD SPRING HARBOR LABORATORY (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2025013911-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, METHOD FOR PRODUCING ARTICLE, AND ARTICLE | ＡＧＣ株式会社 | 2025-01-16 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | disclosed |
| WO-2005079398-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6214609-B1 | CONTACTING RACEMIC BETA AMINO ACID OR ITS ESTER WITH AN ACYL DONOR AND ENZYME UNDER CONDITIONS OT ACYLATE ONE ENANTIOMER TO ITS N-ACYLATED DERIVATIVE | MONSANTO COMPANY | 2001-04-10 | — | — | US | disclosed |
| EP-1051438-A1 | SIDE-CHAIN LIQUID CRYSTALLINE POLYMERS | Ciba SC Holding AG (CH) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037701-A1 | SIDE-CHAIN LIQUID CRYSTALLINE POLYMERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-07-29 | — | — | WO | disclosed |
| US-4486587-A | LIGHFASTNESS, THEROMOSTABILITY | BASF AKTIENGESELLSCHAFT (DE) | 1984-12-04 | — | — | US | disclosed |
| EP-0073007-A1 | Method for the square dimensional concentration of light, and fluorescent compounds | BASF Aktiengesellschaft (DE) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232928-A1 | Drug conjugates | RXRB, NR0B1, RXRA | ALDH1A1 399/4885MAPT 3998/4885CA12 2667/4885 |
| US-12215128-B2 | (Pyridinylmethyl)butanediamine derivatives that chelate copper | PLPBP, PDXK, AOC1 | ALDH1A1 56/4885MAPT 1644/4885CA12 1886/4885 |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | ALDH1A1 610/4885MAPT 4813/4885CA12 2226/4885 |
| US-20260132258-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, METHOD FOR MANUFACTURING ARTICLE, AND ARTICLE | SEM1, PSMA1, CSNK1A1L | ALDH1A1 1886/4885MAPT 4031/4885CA12 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.